This is pilot study which is utilising established KCA expertise in minimal residual disease (MRD), genomics and solid tumours modelling for the preclinical and translational development of liquid biopsies for the molecular monitoring of treatment response in paediatric solid tumours. Specifically, ctDNA, miRNA, CTC and tumour specific epitopes will be monitored.
Started: 1 May 2017
Ending: 30 April 2019
